PDCD1 and esophageal squamous cell carcinoma: Previous subanalyses of other phase 3 trials have also reported prolonged survival with PD-1 inhibitor monotherapy versus chemotherapy as second-line treatment for advanced ESCC in Japanese patients [10, 11].